Cher-Rin Chong1,2, Nigel E Drury1,3,4, Giovanni Licari1,5, Michael P Frenneaux6, John D Horowitz1,2, Domenico Pagano3,4, Benedetta C Sallustio7,8. 1. Cardiology and Clinical Pharmacology Departments, Basil Hetzel Institute, Queen Elizabeth Hospital, Woodville South, South Australia, Australia. 2. Medicine, University of Adelaide, Adelaide, South Australia, Australia. 3. Department of Cardiothoracic Surgery, Queen Elizabeth Hospital Birmingham, Birmingham, UK. 4. School of Clinical & Experimental Medicine, University of Birmingham, Birmingham, UK. 5. Pharmacology, University of Adelaide, Adelaide, South Australia. 6. Norwich Medical School, University of East Anglia, Norwich, UK. 7. Cardiology and Clinical Pharmacology Departments, Basil Hetzel Institute, Queen Elizabeth Hospital, Woodville South, South Australia, Australia. benedetta.sallustio@health.sa.gov.au. 8. Pharmacology, University of Adelaide, Adelaide, South Australia. benedetta.sallustio@health.sa.gov.au.
Abstract
PURPOSE:Perhexiline is a prophylactic anti-ischaemic agent with weak calcium antagonist effect which has been increasingly utilised in the management of refractory angina. The metabolic clearance of perhexiline is modulated by CYP2D6 metaboliser status and stereoselectivity. The current study sought to (1) determine whether the acute accumulation of perhexiline in the myocardium is stereoselective and (2) investigate the relationship between duration of short-term therapy and the potential stereoselective effects of perhexiline within myocardium. METHOD: Patients (n = 129) from the active arm of a randomised controlled trial of preoperative perhexiline in cardiac surgery were treated with oral perhexiline for a median of 9 days. Correlates of atrial and ventricular concentrations of enantiomers were sought via univariate followed by multivariate analyses. RESULTS:Myocardial uptake of both (+) and (-) perhexiline was greater in ventricles than in atria, and there was more rapid clearance of (-) than (+) perhexiline. The main determinants of atrial uptake of both (+) and (-) perhexiline were the plasma concentrations [(+) perhexiline: β = -0.256, p = 0.015; (-) perhexiline: β = -0.347, p = 0.001] and patients' age [(+) perhexiline: β = 0.300, p = 0.004; (-) perhexiline: β = 0.288, p = 0.005]. Atrial uptake of (+) enantiomer also varied directly with duration of therapy (β = 0.228, p = 0.025), while atrial uptake of (-) perhexiline varied inversely with simultaneous heart rate (β = -0.240, p = 0.015). CONCLUSION: (1) Uptake of both perhexiline enantiomers into atrium is greater with advanced age and displays evidence of both saturability and minor stereoselectivity. (2) Atrial uptake of (-) perhexiline may selectively modulate heart rate reduction.
RCT Entities:
PURPOSE:Perhexiline is a prophylactic anti-ischaemic agent with weak calcium antagonist effect which has been increasingly utilised in the management of refractory angina. The metabolic clearance of perhexiline is modulated by CYP2D6 metaboliser status and stereoselectivity. The current study sought to (1) determine whether the acute accumulation of perhexiline in the myocardium is stereoselective and (2) investigate the relationship between duration of short-term therapy and the potential stereoselective effects of perhexiline within myocardium. METHOD:Patients (n = 129) from the active arm of a randomised controlled trial of preoperative perhexiline in cardiac surgery were treated with oral perhexiline for a median of 9 days. Correlates of atrial and ventricular concentrations of enantiomers were sought via univariate followed by multivariate analyses. RESULTS: Myocardial uptake of both (+) and (-) perhexiline was greater in ventricles than in atria, and there was more rapid clearance of (-) than (+) perhexiline. The main determinants of atrial uptake of both (+) and (-) perhexiline were the plasma concentrations [(+) perhexiline: β = -0.256, p = 0.015; (-) perhexiline: β = -0.347, p = 0.001] and patients' age [(+) perhexiline: β = 0.300, p = 0.004; (-) perhexiline: β = 0.288, p = 0.005]. Atrial uptake of (+) enantiomer also varied directly with duration of therapy (β = 0.228, p = 0.025), while atrial uptake of (-) perhexiline varied inversely with simultaneous heart rate (β = -0.240, p = 0.015). CONCLUSION: (1) Uptake of both perhexiline enantiomers into atrium is greater with advanced age and displays evidence of both saturability and minor stereoselectivity. (2) Atrial uptake of (-) perhexiline may selectively modulate heart rate reduction.
Entities:
Keywords:
Drug uptake; Metabolism; Perhexiline; Pharmacokinetics; Stereoselectivity
Authors: Benjamin J Davies; Janet K Coller; Andrew A Somogyi; Robert W Milne; Benedetta C Sallustio Journal: Drug Metab Dispos Date: 2006-10-18 Impact factor: 3.922
Authors: Liang-Han Ling; William Chik; Paula Averbuj; Purendra K Pati; Aaron L Sverdlov; Doan T M Ngo; Raymond G Morris; Benedetta C Sallustio; John D Horowitz Journal: Ther Drug Monit Date: 2011-04 Impact factor: 3.681
Authors: P L Cole; A D Beamer; N McGowan; C O Cantillon; K Benfell; R A Kelly; L H Hartley; T W Smith; E M Antman Journal: Circulation Date: 1990-04 Impact factor: 29.690
Authors: Nigel E Drury; Neil J Howell; Melanie J Calvert; Ralf J M Weber; Eshan L Senanayake; Michael E Lewis; Jonathan A J Hyde; David H Green; Jorge G Mascaro; Ian C Wilson; Timothy R Graham; Stephen J Rooney; Mark R Viant; Nick Freemantle; Michael P Frenneaux; Domenico Pagano Journal: Eur J Cardiothorac Surg Date: 2014-06-19 Impact factor: 4.191
Authors: Bimala Dhakal; Celine Man Ying Li; Runhao Li; Kenny Yeo; Josephine A Wright; Krystyna A Gieniec; Laura Vrbanac; Tarik Sammour; Matthew Lawrence; Michelle Thomas; Mark Lewis; Joanne Perry; Daniel L Worthley; Susan L Woods; Paul Drew; Benedetta C Sallustio; Eric Smith; John D Horowitz; Guy J Maddern; Giovanni Licari; Kevin Fenix Journal: Cancers (Basel) Date: 2022-02-18 Impact factor: 6.639
Authors: Aleksandra A Ageeva; Simon V Babenko; Ilya M Magin; Victor F Plyusnin; Polina S Kuznetsova; Alexander A Stepanov; Sergey F Vasilevsky; Nikolay E Polyakov; Alexander B Doktorov; Tatyana V Leshina Journal: Int J Mol Sci Date: 2020-07-28 Impact factor: 5.923